Facebook
Twitter
LinkedIn
Forward
ASTRO/JASTRO Joint Session: Advances in Liver Cancer Radiation Therapy
The role of this activity reviews growing indications for radiation therapy for liver cancer, educates providers on radiation therapy options (SBRT, particle therapy) and the potential impact of hepatic reserve capacity on decision making, explores challenges and opportunities for clinical trials for liver cancer, discusses heterogeneous liver cancer patient populations, and lastly, discusses a case-based HCC scenario to provide pertinent clinical context, and highlights potential barriers to care including access to care and potential for financial toxicity. Liver cancer occurs on a background of liver disease in a heterogeneous group of people, including minority groups and underserved populations. Efforts will be made to emphasize equitable care and confounding factors that may be associated with biased outcomes following more expensive treatment. This is a joint ASTRO/JASTRO activity that provides a unique opportunity to explore regional differences in patients, treatments and outcomes, as well as potential for fostering collaboration in liver cancer radiation therapy initiatives. The activity is of widespread interest to both community and academic radiation oncologists, as the indications for radiation therapy are expanding. It will also help radiation oncologists to become more aware of tools to aid in the selection and safe treatment of patients with liver cancer, and it fosters collaboration in the multidisciplinary management of this common, yet complicated disease, requiring team care.
Topics:
- Introduction and SBRT for HCC - North America
Laura Ann Dawson, MD, FASTRO - SBRT for HCC - Japan
Tomoki Kimura, MD, PhD - HCC Particle Therapy - Japan
Masashi Mizumoto, MD, PhD - HCC Clinical Trials - North America
Jennifer Y. Wo, MD - Q and A
Hidefumi Aoyama, MD, PhD - Moderator
Laura Ann Dawson, MD, FASTRO - Moderator
Full Panel
This activity is available from February 18, 2025, through 11:59 p.m. Eastern time on February 17, 2027.
The content was originally presented and recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss data that supports different external beam radiation therapy modalities that can effectively treat patients with liver cancer.
- Determine differences in practice patterns globally for radiation therapy for liver cancer.
- Identify patient and tumor factors which may impact treatment selection.
- Hidefumi Aoyama, MD, PhD, is employed by Faculty and Graduate School of Medicine, Hokkaido University. Dr. Aoyama receives grant/research funding from Hitachi High-Teck Corporation.
- Laura Ann Dawson, MD, FASTRO, is employed by Princess Margaret Cancer Centre, University of Toronto. Dr. Dawson receives honoraria from Elekta and AstraZeneca.
- Tomoki Kimura, MD, PhD, is employed by Kochi University Hospital. Dr. Kimura receives honoraria from AstraZeneca.
- Masashi Mizumoto, MD, PhD, is employed by Faculty of Medicine, University of Tsukuba.
- Jennifer Y. Wo, MD, is employed by Massachusetts General Hospital, Harvard Medical School. Dr. Wo receives grant/research funding from Genentech
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until February 17, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.